Protalex is a clinical-stage biopharmaceutical company focused on the development of drugs for treating autoimmune and inflammatory diseases including Rheumatoid Arthritis (RA) and Immune Thrombocytopenia (ITP). Protalex’s lead product, PRTX-100, is a formulation of a proprietary, highly purified form of Staphylococcal Protein A, which is an immunomodulatory protein produced by bacteria. The company was founded in 1999 and is based in Florham Park, New Jersey.